NCCN Guidelines® Insights Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017 Featured Updates to the NCCN Guidelines
NCCN Guidelines® Insights Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017 Featured Updates to the NCCN Guidelines
复制标题
DOI：
10.6004/jnccn.2017.0003
复制
发表时间：
2017-01-01
影响因子：
13.4
通讯作者：
Darlow, Susan
中科院分区：
文献类型：
--
作者：
Daly, Mary B.;Pilarski, Robert;Darlow, Susan
NCCN《遗传/家族性高风险评估肿瘤学临床实践指南：乳腺癌和卵巢癌》为遗传性癌症综合征的基因检测和咨询提供了建议，并为被诊断患有综合征的患者提供了风险管理建议。指南重点关注与乳腺癌和/或卵巢癌风险增加相关的综合征。NCCN遗传/家族性高风险评估：乳腺和卵巢小组至少每年召开一次会议，审查其机构内审稿人的意见，检查出版物和摘要中的相关新数据，并重新评估和更新他们的建议。《NCCN指南见解》总结了专家组关于乳腺癌和/或卵巢癌相关中等渗透性基因突变携带者风险管理的讨论和最新建议。
The NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling for hereditary cancer syndromes and risk management recommendations for patients who are diagnosed with a syndrome. Guidelines focus on syndromes associated with an increased risk of breast and/or ovarian cancer. The NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. The NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding risk management for carriers of moderately penetrant genetic mutations associated with breast and/or ovarian cancer.